Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma

NCT03847896 is registered in ClinicalTrials.gov with Bond Avillion 2 Development LP as lead sponsor.

NCT NCT03847896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma
Lead sponsor
Bond Avillion 2 Development LP
Phase
Phase 3
Overall status
Completed
Start date
March 20, 2019
Completion date
July 20, 2021
Enrollment
1,001 (actual)
Sites
129

Conditions

As the registry lists them; a condition with its own page is linked.

asthma